Clinical Trial Search

Primary: Changes in the Mean BCI for Male From Baseline to Week 12 — 64.604; 61.339; 75.156; 60.513 Score on a scale — p=<0.001

Primary: Number of Participants With Study-related Adverse Events at 6 Months — 2; 1; 1; 1 participants

Primary: Voiding Efficiency — 32; 53; 43; 46 voided percentage — p=1

Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants

Primary: Mean Peak Detrusor Pressures — 58; 31 cm H2O

Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949

Primary: Post-void Residual (PVR) Volume — 101.7; 75.8 mL

Primary: Persistent Retention — 29; 21 participants

Primary: Change in Montreal Cognitive Assessment Total Score — 1.5; 2 units on a scale

Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale

Primary: Change in Urge Incontinence Episodes — 3.9 UUI

Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin

Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722

Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…

Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05

Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016

Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants

Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale

Primary: Feasibility of Study Procedures Measured by Percentage of Participants Starting Intervention Who Complete the Study — 100; 90.4; 100 percentage of participants who…

Primary: Change From Baseline in Maximum Cystometric Capacity at 4 Hours Post Dose 7 on Tolterodine 4 mg and Placebo — 1.15; 0.94 Percentage change — p=0.008

Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11

Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale

Primary: Treatment Phase 1 (Treatment Cycle 1)- Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 6 — -0.18; -3.20 Episodes

Primary: Change From Baseline in Opening Urethral Pressure (OUP) at Day 7 — 49.86; 49.86; 49.86; 47.92 centimeter of water (cmH2O) — p=0.4907

Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05

Primary: Number of Urge Urinary Incontinence (UUI) Episodes — -3.25; -3.89 UUI episodes

Primary: The Rate of Identification of Puborectalis During Ultrasound Scan — 8 Participants

Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07

Primary: Change in Mean Number of Nocturnal Voids From Baseline — -1.63; -1.29 Voids — p=0.112

Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants